Blindness after filler: visual loss and the 90-minute window
The reported distribution of cases, the mechanism, the sixty-to-ninety-minute window, and what the published guidance says to do.
Vision loss after cosmetic filler is rare, has been reported from Asia, Europe and North America, and is in most published cases irreversible. It is the complication that shapes how careful practice is organised.
Mechanism
The eye is supplied by the ophthalmic artery, a branch of the internal carotid. The face is supplied largely by the facial artery, a branch of the external carotid. The two systems anastomose, most importantly where the angular artery meets the dorsal nasal branch at the medial canthus.
Filler injected into a facial artery branch under pressure sufficient to reverse flow travels retrograde past that junction. When injection stops and normal flow resumes, the material is carried into the ophthalmic circulation and occludes the central retinal artery or its branches.
Where the reported cases come from
Review of published cases gives a consistent distribution: glabella 38.8%, nasal region 25.5%, nasolabial fold 13.3%, forehead 12.2%.
The same reviews state plainly that this leaves no safe remainder — there is no facial region from which vision loss has not been reported. The ranking indicates where risk concentrates, not where it ends.
Autologous fat is the material most frequently implicated. Partial visual recovery has been described with hyaluronic acid and calcium hydroxylapatite, though irreversible loss remains the usual outcome across materials.
The window
Once the retinal artery is occluded, the reported interval before blindness becomes irreversible is approximately 60 to 90 minutes. That is shorter than most referral pathways operate, and it is the reason published guidance emphasises immediate recognition and pre-arranged escalation rather than investigation.
Volume
The supratrochlear artery, from the glabella to the orbital apex, holds an average of about 0.085 mL (reported range 0.04–0.12 mL). Injection volume at critical points is kept below this, since a smaller bolus cannot fill the vessel to the orbit. It is the most concrete technique constraint the anatomy provides.
Recognition
Sudden visual change during or immediately after injection. Severe periocular pain. Ophthalmoplegia, ptosis, or a fixed pupil. Skin blanching in the territory of the injected vessel. Any of these is treated as an ophthalmic emergency without waiting for confirmation.
What is described in management
Stop injecting immediately. Escalate to ophthalmology at once — the referral pathway should already exist on paper. High-dose pulsed hyaluronidase to the affected facial territory for hyaluronic acid. Retrobulbar hyaluronidase has been described and has a published anatomical guideline, but it is a specialist technique with limited evidence of retinal benefit and is not a substitute for immediate specialist transfer.
The honest summary of the evidence: outcomes once vision is lost are poor, which is why every element of prevention carries the weight it does.
